How India Aims to Eliminate Hepatitis B and C by 2030
India recently reiterated its national pledge toward hepatitis elimination by the year 2030. Speaking at a high-level United Nations General Assembly side event, Union Health Secretary Punya Salila Srivastava emphasized a people-centred public health framework. In addition, the initiative aligns closely with the United Nations Sustainable Development Goals. Clinicians across India play a pivotal role in this preventive health movement.
India's Roadmap to Hepatitis Elimination by 2030
Under the National Viral Hepatitis Control Programme, India has rapidly expanded decentralized testing and treatment. Consequently, public healthcare facilities now offer free point-of-care screening and antiviral therapies. Furthermore, maternal screening programs actively safeguard neonates against vertical hepatitis B transmission. Healthcare workers must routinely advocate for birth-dose vaccination within twenty-four hours of delivery. Moreover, early detection of hepatitis C allows curative direct-acting antiviral therapy. Therefore, prompt clinical intervention effectively prevents cirrhosis and hepatocellular carcinoma.
CDSCO Advisory on NSAIDs, Antibiotics, and Renal Safety
Meanwhile, the Central Drugs Standard Control Organisation issued a vital regulatory circular. The directive strongly cautions healthcare professionals against the indiscriminate prescription of common painkillers and antimicrobials. Specifically, excessive use of non-steroidal anti-inflammatory drugs contributes significantly to acute kidney injury and chronic kidney disease. In addition, overuse of antibiotics rapidly accelerates antimicrobial resistance across clinical settings. Consequently, regulatory authorities urge practitioners to exercise strict pharmacovigilance and therapeutic restraint.
Enforcing Schedule H and H1 Prescription Regulations
The Directorate General of Health Services highlighted legal obligations under the Drugs Rules, 1945. For instance, most non-steroidal anti-inflammatory drugs belong to Schedule H. Thus, pharmacists cannot dispense these medications without a valid prescription from a registered medical practitioner. Similarly, critical second-line and newer antibiotics fall under Schedule H1. Furthermore, Schedule H1 packaging mandates clear warning labels to deter self-medication. Clinicians should therefore prescribe the lowest effective dose for the shortest necessary duration.
Frequently Asked Questions
Q1: What are India's primary targets for viral hepatitis elimination by 2030?
India aims to eliminate hepatitis B and hepatitis C as major public health threats. Specifically, the government provides decentralized diagnostic testing and free antiviral therapy nationwide.
Q2: Why did CDSCO issue an advisory regarding NSAIDs and antibiotics?
The regulatory authority highlighted that prolonged or indiscriminate use increases the risk of chronic kidney disease. Furthermore, unregulated antibiotic consumption drives widespread antimicrobial resistance.
Q3: How do Schedule H and Schedule H1 rules govern these medications?
Schedule H and Schedule H1 regulations legally prohibit over-the-counter dispensing without a registered practitioner's prescription. In addition, Schedule H1 drugs require distinct warning labels and mandatory pharmacy sales registers.
References
- India reaffirms commitment to eliminate Hepatitis B, C as public health threatsby 2030 - ETHealthworld
- Central Drugs Standard Control Organisation (CDSCO) Advisory on Indiscriminate Use of NSAIDs and Antibiotics - Directorate General of Health Services
- National Viral Hepatitis Control Programme (NVHCP) Operational Guidelines - Ministry of Health and Family Welfare, Government of India
